Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>The efficacy of postoperative treatment of squamous cell carcinoma of the esophagus has not yet been determined. In this retrospective study, we investigated whether postoperative adjuvant chemotherapy (POCT) confers a survival benefit on patients who undergo curative esophagectomy.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>A total of 782 patients were enrolled in our study. The patients were divided into surgery alone (S) and surgery plus postoperative chemotherapy (S + POCT) groups. Propensity score matching (PSM) was used to eliminate the differences in baseline characteristics. The primary endpoint was overall survival (OS), which was calculated by the Kaplan–Meier method and compared with the log‐rank test. A Cox proportional hazards model was used to identify factors influencing the prognosis.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Of 782 patients, 343 (43.9%) underwent S alone, and 439 (56.1%) underwent S + POCT before PSM. The five‐year OS rates were 42.3% and 47.8% in the S and S + POCT groups (<i>p</i> = 0.080), respectively. After PSM (296 patients per group), the five‐year OS rates were 48.7% and 56.2% in the S and S + POCT groups (<i>p</i> = 0.025), respectively. For different cycles of POCT, patients with more than three cycles had a better survival than those with less than three cycles. The significant predictive factors for OS were pN stage (HR = 1.861, 95% CI: 1.310–2.645, <i>p</i> = 0.001), number of dissected nodes (HR = 0.621, 95% CI: 0.494–0.781, <i>p</i> < 0.001) and POCT received (HR = 0.699, 95% CI: 0.559–0.875, <i>p</i> = 0.002), which were identified by multivariate Cox regression analyses in the matched samples. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>POCT appears to improve the OS rate of patients with ESCC after resection, and at least four chemotherapy cycles are necessary. These conclusions warrant further confirmation in large‐scale multicenter randomized controlled trials.</p></section>

Role of radiation therapy in node‐negative esophageal cancer: A propensity‐matched analysis

Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for clinical node‐negative esophageal carcinoma

Is postoperative adjuvant radiotherapy necessary for patients with esophageal cancer after neoadjuvant chemoradiotherapy? An analysis based on the SEER database

Association of the Number of Dissected Lymph Node (LN) with the Survivals of Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC) Patients Received Preoperative Chemoradiotherapy (CRT) Followed by Surgery.

Improved Prognosis with Induction Chemotherapy in Pathological Complete Responders after Trimodality Treatment for Esophageal Squamous Cell Carcinoma: Hypothesis Generating for Adjuvant Treatment.

Long-term Survival of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Esophagectomy Following Neoadjuvant Chemotherapy: a Cohort Study

Neo-adjuvant radiation therapy provides a survival advantage in T3-T4 nodal positive gastric and gastroesophageal junction adenocarcinoma: a SEER database analysis

Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China

Propensity score analysis comparing survival between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma

Number of Retrieved Lymph Nodes during Esophagectomy Affects the Outcome of Stage III Esophageal Cancer in Patients Having Had Pre-Operative Chemo-Radiation Therapy

Prognostic factors for survival in esophageal squamous cell carcinoma (ESCC) patients with a complete regression of the primary tumor (ypT0) after neoadjuvant chemoradiotherapy (NCRT) followed by surgery

Adjuvant treatment patterns for pT3N0M0 esophageal cancer undergoing surgery

Role of chemotherapy after curative esophagectomy in squamous cell carcinoma of the thoracic esophagus: A propensity score‐matched analysis

Comparative Quantitative Lymph Node Assessment in Localized Esophageal Cancer Patients After R0 Resection With and Without Neoadjuvant Chemoradiation Therapy

Postoperative Prophylactic Radiotherapy for N0 Esophageal Squamous Cell Carcinoma

Stage Selection for Neoadjuvant Radiotherapy in Non‐cervical Esophageal Cancer: A Propensity Score‐matched Study Based on the SEER Database

Survival benefit of adjuvant therapy following neoadjuvant therapy in patients with resected esophageal cancer: a retrospective cohort study

Prognostic role of lymph node regression in patients with esophageal cancer undergoing neoadjuvant therapy

Impact of adjuvant chemotherapy for radically resected esophageal squamous cell carcinoma: a propensity score matching analysis

Identification of Optimal Parameters for Assessing Lymph Node Status of Patients with Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy

Neoadjuvant Chemoradiotherapy for T3N0M0 Esophageal Squamous Cell Carcinoma